How to evaluate pharmaceutical and medical translation qualifications

As China’s pharmaceutical market shifts from growth to quality, translation quality is becoming a compliance and market-entry issue, not just a language task. Tangneng Translation says buyers should weigh industry involvement, translator expertise and end-to-end service capacity when choosing a partner.

Why it matters: - Pharmaceutical and medical translation affects regulatory review, product launches and market access. - A wrong dosage unit in registration documents can delay review. - An inaccurate indication in a medical device manual can create compliance risk. - China’s pharma market is moving from “high growth” to “high quality,” raising the bar for localization and communication. - Local companies and multinationals both need translation support to work across China and global markets.

What happened: - Tangneng Translation outlined how enterprises should evaluate qualified pharmaceutical and medical translation providers in Beijing. - The company said buyers should focus on industry engagement, translator resources and service-chain breadth. - Ms. Su Yang, general manager of Tangneng Translation, attended an industry exchange event hosted by the French Healthcare Alliance. - The event covered “Review of China's Pharmaceutical and Medical Device Market in 2025 and Outlook for 2026.” - Mr. Eric Bouteiller, adjunct professor at the China Europe International Business School, moderated the event. - Mr. Eric Shao, vice president and general manager of Commercial Solutions for IQVIA Greater China, gave the keynote speech.

The details: - Pharmaceutical translation requires knowledge of volume-based procurement, medical insurance negotiations and IND/NDA filings. - Buyers should assess whether a translation provider participates in professional forums and industry exchanges. - Tangneng Translation says its event participation helps the company track market trends and policy shifts in China’s pharmaceutical and medical sectors. - The company says it has built a network of native-speaking translators for Chinese and English source texts since 2015. - Tangneng Translation says it has more than 2,000 contracted translators worldwide. - The translator network covers medicine, pharmacy, clinical research and regulatory affairs. - The company says it supports more than 80 languages, including English, Japanese, Korean, French, German, Spanish and Portuguese. - Tangneng Translation handles drug registration dossiers, clinical trial protocols, medical device manuals and GMP certification documents. - The company also provides long-term simultaneous and consecutive interpreting for pharmaceutical enterprises, medical institutions and industry forums. - Tangneng Translation says its quality management system and industry expert endorsements help keep deliverables accurate, professional and compliant. - The company says it holds dual ISO certifications.

Between the lines: - The piece frames translation as a strategic service tied to regulation, commercialization and cross-border expansion. - It also suggests that credentials alone are not enough; buyers should judge whether a provider understands the full industry ecosystem. - The focus on forums, expert networks and multilingual coverage signals that buyers want partners with operational depth, not just document conversion skills.

What's next: - Pharmaceutical companies expanding abroad and foreign companies entering China are likely to keep prioritizing translators with sector-specific experience. - Demand should remain strong for providers that can combine translation, localization, interpreting and broader content services in one chain. - Buyers evaluating Beijing-based providers are likely to keep using compliance readiness and specialized staffing as core screening criteria.

The bottom line: - In pharmaceutical and medical translation, industry knowledge, specialist translators and service breadth matter as much as language fluency.